Serum Vasopressin Levels and Severe Hemorrhagic Shock

Determination of Serum Vasopressin Levels and Correlation With Life-threatening Complications in Adults With Severe Hemorrhagic Shock.

Status

Withdrawn

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01676454

Enrollment

Registered

2012-08-31

Start date

2012-11-30

Completion date

2013-01-31

Last updated

2018-05-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Injury

Keywords

Vasopressin, Trauma, Injury

Brief summary

The purpose of this study is to determine if vasopressin is used up by the body during traumatic shock (severe low blood pressure due to trauma).

Detailed description

For humans suffering trauma and severe hemorrhagic shock, no randomized controlled studies of the effect of exogenous vasopressin use exist, although case reports have suggested it may be of benefit. Even some moribund patients with irreversible shock survived severe hemorrhagic shock after administration of vasopressin. This suggests that at least some patients suffering severe trauma could benefit from AAVP administration. Recently, many clinicians and notable research consortiums have suggested that AVP shows promise for human resuscitation and have called for further human studies. This is a prospective, single-center observational study designed to evaluate (1) whether vasopressin is depleted in severe, but not minor, trauma; and (2) the degree to which endogenous vasopressin levels predict the occurrence of ARDS, sepsis, or death. To test the first hypothesis, serum vasopressin levels (continuous independent variable) will be assessed at enrollment (time 0), 6, 12, 18, and 24 hours later, and correlated with the two levels of trauma (categorical dependent variable). To test the second hypothesis, serum vasopressin levels (now a continuous dependent variable) will be correlated with each of three outcomes-death, ARDS, and sepsis.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

Patients with a minor injury or injuries, defined as: 1. no episodes of systolic blood pressure \< 90 mmHg between occurrence of injury and admission; 2. no blood transfusion requirement; 3. base deficit \< 5 mEq/L; 4. no requirement for mechanical ventilation other than transiently during orthopedic surgery.

Exclusion criteria

1. Pregnancy 2. corticosteroid use, 3. prisoners, and/or 4. head trauma as determined by computed tomography (head trauma may itself induce diabetes insipidus, a marker of pituitary damage and vasopressin deficiency), and/or 5. evidence of spinal cord injury (another cause of vasodilatory shock). Patients will also be excluded if pre-hospital provider information cannot be obtained, or indicates that the trauma occurred more than one 1 hour prior to emergency department admission.

Design outcomes

Primary

Measure	Time frame	Description
Serum vasopressin levels.	24 hours.	6 mL's per blood draw for 5 timepoints=30 mL's total blood drawn.

Countries

United States

Outcome results